Evidence map›Paper›PMID 42864423›Full record

ArticleActa pharmacologica Sinica2026

DYT8 drives lung adenocarcinoma through EGFR-mediated PSMC6 recruitment and uncharacterized phosphorylation at Ser 306 and 525 of c-Src.

Mei-Lian Cai, Meng-Yan Wang, Xiao-Jun Zhao, Yan Xing, Han-Ze Liu, Rong-Guang Shao, Ming-Hua Chen, Wu-Li Zhao

Abstract read
PubMed Publisher
In one paragraph

Article in Acta pharmacologica Sinica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mei-Lian CaiState Key Laboratory of Respiratory Health and Multimorbidity, Key Laboratory of Antibiotic Bioengineering, Ministry of Health, Bejing Key Laboratory of Long-Acting Targeted Delivery Technology and Applications for Peptide and Nucleic Acid Drugs. Laboratory of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China.
Meng-Yan WangState Key Laboratory of Respiratory Health and Multimorbidity, Key Laboratory of Antibiotic Bioengineering, Ministry of Health, Bejing Key Laboratory of Long-Acting Targeted Delivery Technology and Applications for Peptide and Nucleic Acid Drugs. Laboratory of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China.
Xiao-Jun ZhaoState Key Laboratory of Respiratory Health and Multimorbidity, Key Laboratory of Antibiotic Bioengineering, Ministry of Health, Bejing Key Laboratory of Long-Acting Targeted Delivery Technology and Applications for Peptide and Nucleic Acid Drugs. Laboratory of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China.
Yan XingDepartment of Pediatrics, Peking University Third Hospital, Beijing, 100083, China.
Han-Ze LiuSchool of Basic Medical Sciences, Harbin Medical University, Harbin, 150081, China.
Rong-Guang ShaoState Key Laboratory of Respiratory Health and Multimorbidity, Key Laboratory of Antibiotic Bioengineering, Ministry of Health, Bejing Key Laboratory of Long-Acting Targeted Delivery Technology and Applications for Peptide and Nucleic Acid Drugs. Laboratory of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China.
Ming-Hua ChenBeijing Key Laboratory of Technology and Application for Anti-Infective New Drugs Research and Development, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China. chenminghua@imb.pumc.edu.cn.
Wu-Li ZhaoState Key Laboratory of Respiratory Health and Multimorbidity, Key Laboratory of Antibiotic Bioengineering, Ministry of Health, Bejing Key Laboratory of Long-Acting Targeted Delivery Technology and Applications for Peptide and Nucleic Acid Drugs. Laboratory of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China. Wenlyzh@imb.pumc.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung adenocarcinoma (LUAD) is a multi-kinase hyperactivation-driven malignancy. Targeted therapies are effective but have limited application, primarily due to a small eligible patient population and the development of drug resistance. Analysis of TCGA and tissue microarray show that Dystonia 8 (DYT8) is specially highly expressed in more than 70% of LUAD patients. Furthermore, increased DYT8 expression is positively associated with tumor malignancy and negatively associated with survival. Using the Dyt8 knock-in (cKras

Indexed as

DYT8EGFRlung adenocarcinomaPSMC6resistanceSrc

Identifiers

PMID42864423

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.